Profile data is unavailable for this security.
About the company
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
- Revenue in SEK (TTM)3.98m
- Net income in SEK-77.82m
- Incorporated1987
- Employees10.00
- LocationMedivir ABLunastigen 5, 2 trHUDDINGE 141 22SwedenSWE
- Phone+46 854683100
- Fax+46 84076439
- Websitehttps://www.medivir.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initiator Pharma A/S | 0.00 | -16.50m | 204.73m | 2.00 | -- | 4.44 | -- | -- | -0.274 | -0.274 | 0.00 | 0.6736 | 0.00 | -- | -- | 0.00 | -43.00 | -67.58 | -46.15 | -73.43 | -- | -- | -- | -- | -- | -- | 0.0619 | -- | -- | -- | 53.32 | -- | -- | -- |
| Xbrane Biopharma AB | 209.08m | -72.86m | 214.30m | 26.00 | -- | 0.365 | -- | 1.02 | -5.16 | 8.99 | 14.57 | 28.49 | 0.2713 | 0.2899 | 5.00 | 3,216,539.00 | -9.46 | -37.48 | -15.30 | -65.13 | 71.25 | -- | -34.85 | -233.69 | 1.71 | -1.49 | 0.00 | -- | -16.76 | -- | 17.70 | -- | 113.17 | -- |
| Dextech Medical AB | 0.00 | -4.96m | 218.13m | 1.00 | -- | 9.12 | -- | -- | -0.2684 | -0.2684 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -18.58 | -19.36 | -18.94 | -19.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.96 | -- | 40.14 | -- |
| AlzeCure Pharma AB | 0.00 | -39.20m | 218.34m | 11.00 | -- | 4.31 | -- | -- | -0.4047 | -0.4047 | 0.00 | 0.4409 | 0.00 | -- | -- | 0.00 | -71.83 | -73.70 | -88.08 | -83.65 | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | 5.20 | -- | -38.94 | -- |
| Klaria Pharma Holding AB (publ) | 11.23m | -58.70m | 227.77m | 4.00 | -- | 50.12 | -- | 20.28 | -0.4069 | -0.3093 | 0.0699 | 0.0185 | 0.201 | -- | 5.34 | 2,808,250.00 | -105.02 | -48.20 | -649.38 | -74.06 | -- | -- | -522.58 | -1,522.52 | -- | -2.47 | 0.1195 | -- | -73.41 | -11.85 | -33.44 | -- | -- | -- |
| Promimic AB | 45.57m | -12.13m | 247.49m | 18.00 | -- | 4.06 | -- | 5.43 | -0.6388 | -0.6388 | 2.40 | 3.23 | 0.603 | -3.56 | 3.62 | 2,398,421.00 | -16.05 | -20.50 | -18.57 | -24.44 | 105.07 | 104.49 | -26.62 | -59.75 | 3.52 | -- | 0.00 | -- | 18.63 | 50.25 | -36.09 | -- | -- | -- |
| Xintela AB | 2.96m | -42.28m | 248.04m | 13.00 | -- | -- | -- | 83.88 | -0.0665 | -0.0665 | 0.0046 | -0.0396 | 0.3486 | -- | 6.47 | 227,461.50 | -498.42 | -194.17 | -- | -651.77 | 100.00 | -- | -1,429.86 | -6,272.93 | -- | -16.40 | -- | -- | 5,303.85 | 156.45 | 27.54 | -- | -- | -- |
| Bio-Works Technologies AB | 41.41m | -29.78m | 258.33m | 29.00 | -- | 7.04 | -- | 6.24 | -0.50 | -0.50 | 0.5878 | 0.3738 | 0.6931 | 0.9866 | 6.45 | 1,380,200.00 | -49.84 | -50.49 | -67.92 | -61.39 | 72.68 | 70.42 | -71.91 | -140.95 | 1.65 | -- | 0.00 | -- | -41.99 | 35.51 | 34.25 | -- | -48.46 | -- |
| Mendus AB (publ) | 0.00 | -103.70m | 316.05m | 29.00 | -- | 0.4446 | -- | -- | -2.06 | -2.06 | 0.00 | 11.36 | 0.00 | -- | -- | 0.00 | -15.49 | -18.52 | -16.08 | -19.67 | -- | -- | -- | -32,968.84 | -- | -- | 0.0339 | -- | -- | -- | -26.35 | -- | 17.80 | -- |
| Intervacc AB | 21.09m | -63.31m | 317.30m | 15.00 | -- | 1.02 | -- | 15.04 | -0.3776 | -0.3776 | 0.09 | 0.911 | 0.079 | 0.8382 | 3.54 | 1,406,067.00 | -23.70 | -20.93 | -25.78 | -22.44 | 29.03 | -7.76 | -300.17 | -753.03 | 9.53 | -- | 0.0003 | -- | 47.06 | -0.5868 | 26.58 | -- | -52.41 | -- |
| Zelluna ASA | 4.66k | -198.30m | 366.88m | 26.00 | -- | 4.86 | -- | 78,767.38 | -38.70 | -38.70 | 0.0004 | 3.08 | 0.00003 | -- | 0.001 | 416.67 | -144.37 | -36.03 | -159.75 | -39.51 | -- | -- | -4,257,300.00 | -- | -- | -- | 0.0162 | -- | -- | -- | -6.25 | -- | -37.05 | -- |
| Ascelia Pharma AB | 0.00 | -76.25m | 371.09m | 11.00 | -- | 3.76 | -- | -- | -0.693 | -0.693 | 0.00 | 0.7777 | 0.00 | -- | -- | -- | -60.31 | -54.24 | -85.44 | -64.44 | -- | -- | -- | -- | -- | -31.70 | 0.0097 | -- | -- | -- | 4.72 | -- | -32.17 | -- |
| Medivir AB | 3.98m | -77.82m | 398.42m | 10.00 | -- | 1.52 | -- | 100.01 | -0.6789 | -0.6789 | 0.0348 | 0.5831 | 0.0238 | -- | 0.9374 | 398,400.00 | -46.44 | -31.75 | -69.67 | -38.14 | -- | -- | -1,953.24 | -740.12 | -- | -70.04 | 0.00 | -- | -54.36 | -16.77 | -38.06 | -- | -- | -- |
| Herantis Pharma Oyj | 0.00 | -57.97m | 573.73m | 13.00 | -- | 30.86 | -- | -- | -0.2417 | -0.2417 | 0.00 | 0.0726 | 0.00 | -- | -- | 0.00 | -124.50 | -81.63 | -166.61 | -107.95 | -- | -- | -- | -- | -- | -17.91 | 0.6101 | -- | -- | -- | -1,865.03 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Medivir AB's reporting currency: Swedish Krona SEK
3.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nordea Investment Management ABas of 31 Oct 2025 | 10.38m | 2.31% |
| Handelsbanken Fonder ABas of 31 Dec 2025 | 2.66m | 0.59% |
| Atle Fund Management ABas of 31 Dec 2024 | 2.19m | 0.49% |
| SEB Funds ABas of 31 Dec 2025 | 1.09m | 0.24% |
| Skandia Investment Management ABas of 28 Nov 2025 | 714.08k | 0.16% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 108.42k | 0.02% |
| Skandia Fonder ABas of 28 Nov 2025 | 20.37k | 0.01% |
| Evli Fund Management Co. Ltd.as of 30 Aug 2024 | 12.22k | 0.00% |
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
